Differences in consumption of psychotropis drugs in depression disorders: ethnic aspects

Svetlana A. Stepanyan; Eleonora A. Manvelyan; Mikael M. Manvelyan; Vladimir B. Yarovitskii; Saniyat A. Chagarova

doi:10.17816/RCF191119-122

Reviews on Clinical Pharmacology and Drug Therapy ›› 2021, Vol. 19 ›› Issue (1) : 119 -122. DOI: 10.17816/RCF191119-122

Short communications

research-article

Differences in consumption of psychotropis drugs in depression disorders: ethnic aspects

Author information +

History +

PDF

Abstract

In the pharmacotherapy of depressive disorders, drug consumption was maximal in the group of Slavs, less in the groups of Karachays, Turkmens, Nogais, and minimal in the group of Armenians.

Keywords

depressive disorder / psychotropic drugs / drug consumption / ethnic groups

Cite this article

Download citation ▾

Svetlana A. Stepanyan, Eleonora A. Manvelyan, Mikael M. Manvelyan, Vladimir B. Yarovitskii, Saniyat A. Chagarova. Differences in consumption of psychotropis drugs in depression disorders: ethnic aspects. Reviews on Clinical Pharmacology and Drug Therapy, 2021, 19(1): 119-122 DOI:10.17816/RCF191119-122

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43(3):471–481. DOI: 10.1371/journal.pmed. 1001547

[2]	Ferrari A.J., Somerville A.J., Baxter A.J., et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature // Psychol Med. 2013. Vol. 43. No 3. P. 471–481. DOI: 10.1371/journal.pmed. 1001547

[3]	Shah RR. Inter-ethnic differences in drug response: Implications for drug development and complying with drug regulation. Clin Res Regul Aff. 2015;32(3):88–98. DOI: 10.3109/10601333.2015. 1064131

[4]	Shah R.R. Inter-ethnic differences in drug response: Implications for drug development and complying with drug regulation // Clin Res Regul Aff. 2015. Vol. 32. No 3. P. 88–98. DOI: 10.3109/10601333. 2015.1064131

[5]	Ferdinand KC, Igari M. The role of racial/ethnic factors in global clinical trials. Expert Rev Clin Pharmacol. 2018;11(9):829–832. DOI: 10.1080/17512433.2018.1510311

[6]	Ferdinand K.C., Igari M. The role of racial/ethnic factors in global clinical trials // Expert Rev Clin Pharmacol. 2018. Vol. 11. No. 9. P. 829–832. DOI: 10.1080/17512433.2018.1510311

[7]	Baturin VA, Manvelyan EA, Yarovitskiy VB, Stepanyan SA. Personifitsirovannyy podkhod k primeneniyu antidepressantov pri depressivnykh rasstroystvakh. Stavropol’: StGMU; 2019. 44 p. (In Russ.)

[8]	Батурин В.А., Манвелян Э.А., Яровицкий В.Б., Степанян С.А. Персонифицированный подход к применению антидепрессантов при депрессивных расстройствах. Ставрополь: СтГМУ, 2019. 44 с.

[9]	WHO Collaborating Centre for Drug Statistics Methodology [internet]. ATC/DDD Index 2021. Available from: http://www.whocc.no/atc_ddd_index/. Cited: 2021 Feb 15.

[10]	WHO Collaborating Centre for Drug Statistics Methodology. [интернет] ATC/DDD Index 2021. Режим доступа: http://www.whocc.no/atc_ddd_index/. Дата обращения: 15.02.2021.